Journal of Hematology & Thromboembolic Diseases
Open Access

Abstract

Insufficient Efficiency of Prasugrel in Diabetic Patients with Acute STEMI Undergoing pPCI of Culprit Coronary Lesion – Review of Current Knowledge

Samos M, Fedor M, Kovar F, Duraj L, Skornova I, Fedorova J, Galajda P, Stasko J, Bolek T, Kubisz P and Mokan M

The activation and subsequent platelet aggregation plays a key role in the formation of arterial thrombosis and therefore is the key therapeutic target in the treatment of acute coronary syndromes. Dual antiplatelet therapy containing aspirin and P2Y12 ADP receptor antagonist forms currently the basis in acute ST – elevation myocardial infarction (STEMI) pharmacological treatment. Nevertheless, there is a wide variability in pharmacodynamic response to administration of clopidogrel, the most frequently used P2Y12 ADP receptor antagonist. High platelet reactivity after clopidogrel administration is associated with increased risk of in - stent thrombosis and points to the suitability of laboratory monitoring of antiplatelet therapy effectivity in clinical practice. Laboratory monitoring of antiplatelet therapy by ex vivo platelet function tests may help to identify individuals with poor antiplatlet response. Recently, there is growing number of data reporting a failure in antiplatelet response following clopidogrel administration, which is specifically associated with insulin resistance and diabetes mellitus. Prasugrel, a new, potent P2Y12 ADP receptor antagonist, provides faster and more consistent inhibition of platelet function compared with clopidogrel. Prasugrel therapy was repeatedly described as an effective method to overcome clopidogrel resistance and prasugrel resistance has not yet been reliably described. Article gives a review about prasugrel resistance and its role in acute coronary syndrome patients.